Aggregated α-synuclein plays an important role in Parkinson's disease pathogenesis. Cinpanemab, a human-derived monoclonal antibody that binds to α-synuclein, is being evaluated as a disease-modifying treatment for Parkinson's disease.

Trial of Cinpanemab in Early Parkinson's Disease

Zappia, Mario
Membro del Collaboration Group
2022-01-01

Abstract

Aggregated α-synuclein plays an important role in Parkinson's disease pathogenesis. Cinpanemab, a human-derived monoclonal antibody that binds to α-synuclein, is being evaluated as a disease-modifying treatment for Parkinson's disease.
2022
Antibodies, Monoclonal
Double-Blind Method
Humans
Treatment Outcome
Antibodies, Monoclonal, Humanized
Antiparkinson Agents
Parkinson Disease
alpha-Synuclein
File in questo prodotto:
File Dimensione Formato  
Trial of cinpanemab...pdf

accesso aperto

Tipologia: Versione Editoriale (PDF)
Dimensione 602.63 kB
Formato Adobe PDF
602.63 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.11769/549743
Citazioni
  • ???jsp.display-item.citation.pmc??? 9
  • Scopus 127
  • ???jsp.display-item.citation.isi??? 118
social impact